Eric B. Lev
Eric, who joined Ampersand in 2013, has 18 years of middle market healthcare investment experience. Eric’s current and past board seats include Alliance Pharma, ALPCO, Biosynth, CutisPharma, Genoptix, Interpace Diagnostics, Iuovo Biosciences, LakePharma, Leinco Technologies, Nexelis, Nexcelom Biosciences, and P95. Prior to Ampersand, he spent seven years as a member of the investment team at Water Street Healthcare Partners. Prior to Water Street, Eric worked at Beckman Coulter and at One Equity Partners. Eric holds a B.A. in Economics from Northwestern University and a M.B.A. from the University of Chicago.